Scholarlink

<p>Osteoporotic fractures are a&#xa0;major cause of morbidity, functional decline, and mortality in older adults. Despite effective treatment options, a&#xa0;substantial treatment gap persists in primary and secondary fracture prevention. Osteoanabolic agents stimulate bone formation and lead to a rapid improvement in bone mineral density and bone microarchitecture. Clinical trials demonstrate superiority over antiresorptive therapies in patients at very high or imminent risk of fracture; however, treatment in geriatric populations requires a differentiated balancing of the benefit-risk ratio with careful consideration of comorbidities, administration feasibility and cardiovascular safety. This CME article provides a&#xa0;clinically oriented overview of mechanisms of action, efficacy, safety and practical decision strategies for osteoanabolic treatment in older individuals.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anabole Therapie bei geriatrischen Patient:Innen mit Osteoporose

  • 期刊论文

  • 发表日期：

    2026年7月8日

查看全文
  • Judith Haschka

摘要

Osteoporotic fractures are a major cause of morbidity, functional decline, and mortality in older adults. Despite effective treatment options, a substantial treatment gap persists in primary and secondary fracture prevention. Osteoanabolic agents stimulate bone formation and lead to a rapid improvement in bone mineral density and bone microarchitecture. Clinical trials demonstrate superiority over antiresorptive therapies in patients at very high or imminent risk of fracture; however, treatment in geriatric populations requires a differentiated balancing of the benefit-risk ratio with careful consideration of comorbidities, administration feasibility and cardiovascular safety. This CME article provides a clinically oriented overview of mechanisms of action, efficacy, safety and practical decision strategies for osteoanabolic treatment in older individuals.